Dispe	nse	ProA	<b>\ir</b> ®	HFA	
the #1	lalb	utero	ol ir	nhale	er <sup>1</sup>


# LINKS www.ProAirHFA.com www.Switch2HFA.com Save your qualified patients up to \$100 off ProAir HFA\* Prescribing Information

### \*Up to \$20 off their next 5 prescriptions

# ProAir HFA offers more access...


- Preferred on 82% of commercial formularies<sup>2</sup> – means patients pay the lowest out-of-pocket costs
- Covered on 91% of commercial formularies<sup>2</sup> – means ProAir HFA is available to more patients

# ProAir HFA



Ventolin<sup>®</sup> HFA

Xopenex HFA®




Preferred brands by formulary

0% |10% |20% |30% |40% |50% |60% |70% |80% |90%

## ...and prescriptions

 Over 14 million in 2008 – more than all other albuterol HFA inhalers combined<sup>1</sup> Proventil HFA Proventil HFA Xopenex HFA Ventolin HFA



Total prescriptions dispensed since

January 2008 (in millions)<sup>1</sup>

### More access, more prescriptions, and more reasons to dispense ProAir HFA.

ProAir<sup>®</sup> HFA is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

### Important Safety Information

- Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life-threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
- Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
- ProAir<sup>®</sup> HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes.
- Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors, and tricyclic antidepressants.
- Do not exceed the recommended dose.
- Adverse events, which occurred at an incidence rate of at least 3% with ProAir® HFA, include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis.

**REFERENCES:** 1. IMS Health National Prescription Audit, TRx Data, November 2008. 2. Business One Technologies. December 29, 2008.



Inhalation Aerosol





The brands listed are the registered trademarks of their respective owners. ProAir® HFA is a registered trademark of Teva Specialty Pharmaceuticals LLC. ©2009 Teva Specialty Pharmaceuticals LLC. 090045